Polymer-drug conjugates as nano-sized medicines

► Polymer therapeutics are considered amongst the most successful nanomedicines. ► Future directions: new targets, combination therapy, controlled polymer architecture, advanced characterization techniques. ► An exponentially growing industrial pipeline on nanoconjugates is currently available. ► Understanding nanoconjugate features that govern clinical risk-benefit is leading to clinical biomarkers. ► Opaxio™ first example of individualized medicine with polymer-drug conjugates.